ASP Isotopes Previews Q2 Results, Sets $330M-$700M 2031 EBITDA Target, and Flags Helium Production by September
ASPI sits 21% above its 52-week low of $3.51.
Summary
ASP Isotopes issued a shareholder letter previewing Q2 2026 results, forecasting PET Labs revenue of ~$14M (up from $6M), helium production by September 30, and a 2031 EBITDA target of $330M-$700M. The update provides concrete timelines and financial targets that reduce uncertainty around the company's transition to commercial production.
Key Events · Earnings and Guidance · ASPI
-
PET Labs Revenue Surge
1H 2026 organic revenue growth exceeded 50%, with FY 2026 revenue forecast at ~$14M, up from $6M in 2025. The division is on track toward a $50-100M EBITDA target by 2031.
-
Helium Production Imminent
Renergen expects to commence helium production before September 30, 2026. Phase 1 annualized helium and LNG revenues are projected at ~$27M, with Phase 2 construction starting in 2H 2026 and potential annual revenues exceeding $360M at nameplate capacity.
-
2031 EBITDA Target Set at $330M-$700M
Management provided long-term aspirational EBITDA targets of $330M-$700M by 2031, driven by radiopharmaceuticals, electronic gases, and natural gas, excluding nuclear fuels.
-
Stable Isotope Shipments in 2H 2026
Silicon-28 and Ytterbium-176 enrichment facilities are in final stages of commercial production, with initial product shipments expected in the second half of 2026. Carbon-14 enrichment is also expected to begin upon receipt of feedstock.
Analysis · ASPI · Industrial Applications And Services
The shareholder letter provides the first detailed operational update since the Q1 10-Q, revealing that PET Labs revenue is on track to nearly triple to $14M in 2026, Renergen helium production will start within two months, and the company is targeting $330M-$700M in EBITDA by 2031. These disclosures materially de-risk the near-term revenue ramp and validate the sum-of-the-parts thesis, especially against a backdrop of prior cash burn and covenant breaches. The letter also quantifies Phase 2 helium economics (>$360M annual revenue potential) and outlines a clear path to separate listings for Noble Africa and QLE, which could unlock significant value.
How filings like this one have moved
In the 30 days to Oct 25, 2026, 37% of the 945 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.78%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ASPI was trading at $4.26 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $521.2M. The 52-week trading range was $3.51 to $14.49. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.